Vaginal DNA Assay Shows Promise - Summary - MDSpire
From the Journals

Vaginal DNA Assay Shows Promise

A two-marker methylated DNA assay identified endometrial cancer with 96% sensitivity in self-collected vaginal fluid — but prospective validation is needed before it can reduce biopsies in routine care.

  • By

  • Kerri Miller

  • May 8, 2026

  • 14 min

Share

Researchers at Mayo Clinic have developed a two-marker methylated DNA assay that detects endometrial cancer with 96% sensitivity and 82% specificity using self-collected vaginal fluid samples. The study, involving 15 institutions and published in Gynecologic Oncology, highlights the potential for improved diagnosis amid existing limitations of current methods like endometrial biopsy. However, the findings are from a case-control study and require further validation to assess negative predictive value and clinical applicability.

Original Source(s)

Vaginal DNA Assay Shows Promise

  • by Kerri Miller

  • May 8, 2026

Related Content

Premenstrual Disorders Linked to Broad Psychiatric Risk

Swedish study finds two-way associations between premenstrual disorders and psychiatric conditions, with strongest links involving depression, anxiety, attention-deficit/hyperactivity disorder, bipolar disorder, and personality disorders.

31 Live Births Reported Following Uterus Transplant

Single-center series details maternal, obstetric, and neonatal outcomes among recipients with uterine-factor infertility

Cervical Cancer Trends Differ by Age

Recent declines among women younger than 35 years contrasted with rising long-term incidence among women aged 35 to 49 years in Puerto Rico